In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schwarz Pharma AG

Latest From Schwarz Pharma AG

UCB Links With Daiichi Sankyo For Epilepsy In Japan

UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.

BioPharmaceutical Japan

UAE Drug Regulator Orders Recall Of Schwarz Pharma Heart Drug

The United Arab Emirates ordered a recall of Germany-based Schwarz Pharma's Nitrocine (glyceryl trinitrate) for treating heart and blood-pressure problems on grounds it may contain impurities.

BioPharmaceutical Middle East and Africa

Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

BioPharmaceutical Regulation

CEO Interview: AstraZeneca's David Brennan

David Brennan has sharpened AstraZeneca's therapeutic area focus and embraced external R&D. The next two years will determine whether the productivity drive is working--or if more radical change is needed.

BioPharmaceutical Europe
See All

Company Information